Chapter category: Oncology
Lipid A in Cancer Therapies Preclinical Results
Lipid A in Cancer Therapy
Edited by: Jean-François JeanninISBN: TBA
» Get more information about this book at landesbioscience.com «
Chapter authors:
Daniéle Reisser
Studies in animal models showed that the antitumoral effect of LPS and of their biologically active moiety, lipid A, is indirect and relies on the induction of an immune response both innate and specific, leading to cytokine production. They also affect tumor development by inhibiting tumor blood flow and induce necrosis as well as apoptosis of tumor cells. Lipids A have been tested in animals, either alone or as adjuvant in therapeutic vaccines. The efficacy of treatments depends on the type of molecule and on the protocol. In general, increased survival was obtained, accompanied in some cases by tumor regression and cure.
Daniéle Reisser
Cancer Immunotherapy Research Laboratory, Ecole Pratique des Hautes Etudes
Additional chapters from this book:
Conformation and Supramolecular Structure of Lipid A
Klaus Brandenburg and Ulrich Seydel
In recent years, lipid A as ‘endotoxic principle’ of bacterial lipopolysaccharide (LPS) and derivatives thereof have become increasingly important in the field of biomedical application such as for va...
Interactions between Lipid A and Serum Proteins
Jörg Andrä, Thomas Gutsmann, Mareike Müller and Andra B. Schromm
Entry of endotoxin (lipopolysaccharide (LPS) or lipid A) into the blood stream is causative for the emergence of sepsis and septic shock with all its pathophysiological consequences.1 Serum contains a...
The Lipid A Receptor
Kiyoshi Takeda
The lipid A receptor consists of several subunits. Lipopolysaccharide binding protein (LBP) is a serum protein facilitating association of lipid A with CD14. The Lipid A-LBP-CD14 complex is further de...
Lipid A in Cancer Therapies Preclinical Results
Daniéle Reisser
Studies in animal models showed that the antitumoral effect of LPS and of their biologically active moiety, lipid A, is indirect and relies on the induction of an immune response both innate and speci...
Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti‑Cancer Vaccines: Clinical Results
Christopher W. Cluff
A variety of vaccines designed for cancer immunotherapy have been tested in clinical trials for more than two decades. Investigators realized early on that addition of adjuvants to cancer vaccines wou...
Antitumoral Effects of Lipids A, Clinical Studies
Marc Bardou and Daniéle Reisser
Cancer remains the second leading cause of death, after cardiovascular diseases, in industrialized countries. The first goal to achieve is to prevent cancer occurrence or to diagnose it at an early an...
Lipid A-Mediated Tolerance and Cancer Therapy
Cheryl E. Rockwell, David. C. Morrison and Nilofer Qureshi
The occurrence of tolerance or host unresponsiveness in animals and humans administered multiple doses of microbe or microbial products has long been recognized by scientists and physicians with publi...
Lipid A Receptor TLR4‑Mediated Signaling Pathways
Masahiro Yamamoto and Shizuo Akira
Lipid A is a strong activator of monocytes to release immune stimulators such as proinflammatory cytokines. Overproduction of inflammatory cytokines such as TNF and IL‑6 is known to cause septic...
Structure and Synthesis of Lipid A
Shoichi Kusumoto, Masahito Hashimoto and Kazuyoshi Kawahara
Lipid A is the lipophilic partial structure of bacterial lipopolysaccharide (LPS), which is a characteristic and essential component of the cell surface architecture of Gram negative bacteria. LPS con...
